Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.